HHC For Cancer
Some studies have suggested that HHC may have potential as an anti-cancer agent, although the evidence is still preliminary and more research is needed to determine the safety and effectiveness of HHC for this purpose.
A review published in the journal Nature Reviews Cancer in 2003 discussed the potential of cannabinoids, including HHC, as anticancer agents. The author of the review noted that HHC may have anti-tumor effects, although more research is needed to confirm this effect.
A study published in the British Journal of Pharmacology in 2012 found that HHC and other cannabinoids inhibited the growth of glioma cells in culture and in animal models, and that this effect was mediated by the CB1 cannabinoid receptor. The authors of the study concluded that the CB1 receptor may be a potential target for the treatment of gliomas.
A study published in the journal Oncogene in 2008 found that HHC inhibited the migration of lung cancer cells in culture and the growth and metastasis of lung cancer in animal models. The authors of the study concluded that HHC may have potential as an anti-cancer agent.
Overall, these studies suggest that HHC may have potential as an anti-cancer agent, although more research is needed to confirm this effect and to determine the optimal dosing and administration of HHC for this purpose. If you are interested in using HHC for cancer, it is important to speak with a healthcare professional for guidance.
- Guzman, M. (2003). Cannabinoids: potential anticancer agents. Nature Reviews Cancer, 3(10), 745-755.
- Velasco, G., Sánchez, C., Guzmán, M., & Galve-Roperh, I. (2012). The CB1 cannabinoid receptor as a target for the treatment of gliomas. British Journal of Pharmacology, 167(4), 549-566.
- Preet, A., Ganju, R. K., & Groopman, J. E. (2008). Delta-9-tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene, 27(47), 5965-5973.